ଭାଇଲାଜୋଡନ

ଭାଇଲାଜୋଡନ
Clinical data
Pronunciation	/ˈvaɪbrɪd/ VY-brid
Trade names	Viibryd
Synonyms	EMD-68843; SB-659746A
AHFS/Drugs.com	monograph
MedlinePlus	a611020
data	US DailyMed: 4c55ccfb-c4cf-11df-851a-0800200c9a66;
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth
Drug class	Serotonin modulator
ATC code	N06AX24 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	72% (oral, with food)
Metabolism	Hepatic via CYP3A4
Elimination half-life	25 hours
Excretion	Faecal and renal
Identifiers
	IUPAC name 5-(4-[4-(5-Cyano-1H-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide;
CAS Number	163521-12-8 ;
PubChem CID	6918313;
IUPHAR/BPS	7427;
ChemSpider	5293518 ;
UNII	S239O2OOV3;
KEGG	D09698 ;
ChEBI	CHEBI:70707 ;
ChEMBL	CHEMBL439849 ;
Chemical and physical data
Formula	C26H27N5O2
Molar mass	441.524 g/mol
3D model (JSmol)	Interactive image;
	SMILES N#Cc5ccc4[nH]cc(CCCCN3CCN(c2ccc1oc(C(N)=O)cc1c2)CC3)c4c5;
	InChI InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32) ; Key:SGEGOXDYSFKCPT-UHFFFAOYSA-N ;
(what is this?) (verify)

ଭାଇଲାଜୋଡନ Vilazodone, ଏକ ବିକ୍ରୟ ନାମ ଭାଇବ୍ରିଡ/ Viibryd) ଏକ ଔଷଧ ଯାହା ପ୍ରମୁଖ ଅବସାଦ ବେମାରୀର ଚିକିତ୍ସାରେ ବ୍ୟବ‌ହାର କରାଯାଏ ।^[୧] ଜେନେରାଲାଇଜଡ ଆଙ୍ଗଜାଇଟି ଡିଜଅର୍ଡ଼ର (generalized anxiety disorder) ରୋଗର ଚିକିତ୍ସା ନିମନ୍ତେ ହେଉଥିବା ଏହାର ଅନୁଶୀଳନ ସନ ୧୯୧୭ରେ ବନ୍ଦ କରିଦିଆଗଲା ।^[୩] ପାଟିରେ ଏହି ଔଷଧ ଦିଆଯାଏ ।^[୧]

ଭାଇଲାଜୋଡନର ସାଧାରଣ ପ୍ରତିକ୍ରିୟରେ ଅଇ ତରଳ ଝାଡ଼ା ଓ ନିଦ୍ରା ସମସ୍ୟା ହୋଇପାରେ ।^[୧] ପ୍ରତିକ୍ରିୟା ସାଂଘାତିକ ହେଲେ ୨୫ ବର୍ଷ ବୟସରୁ କମ୍ ଲୋକମାନଙ୍କର ଆତ୍ମହତ୍ୟା ପ୍ରବଣ, ମାନିଆ, ସେରୋଟୋନିନ ସିଣ୍ଡ୍ରୋମ, ରକ୍ତସ୍ରାବ ଓ ଏସଆଇଡିଏଚ (SIADH) ହୋଇପାରେ ।^[୧] ଏହାର ମାତ୍ରା ଦୃତ ଗତିରେ କମେଇଲେ ଅବସାଦରୋଧୀ ବିରତି ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ । ^[୧] ଗର୍ଭାବସ୍ଥା ଓ ସ୍ତନ୍ୟପାନ କରେଇବା ସମୟରେ ଏହାର ସେବନ ନିଷେଧ । ^[୪] ଏହା ଏକ ସେରୋଟୋନିନ ମୋଡ୍ୟୁଲେଟର (serotonin modulator) ଶ୍ରେଣୀର ଔଷଧ ଯାହା ଏସଏସଆରଆଇ (SSRI) ଭାବରେ ଓ ୫-ଏଚଟି୧ଏ ରିସେପ୍ଟରକୁ (5-HT_1A receptor|) ସକ୍ରିୟ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୧]

ଭାଇଲାଜୋଡନ ସନ ୨୦୧୧ରେ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ସ୍ୱୀକୃତ ହୋଇଥିଲା ।^[୧] ସନ ୨୦୧୬ ସୁଦ୍ଧା ଏହା ଅନ୍ୟାନ୍ୟ ଦେଶମାନଙ୍କରେ ସ୍ୱୀକୃତ ହୋଇନାହିଁ ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହି ଔଷଧ ବାବଦ ଏକ ମାସରେ ପ୍ରାୟ ୨୬୧ ଆମେରିକୀୟ ଡଲାର ଖର୍ଚ୍ଚ ହୁଏ ।^[୬] ସନ ୨୦୧୬ରେ ଏହାର ୧ ନିୟୁତରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ ହୋଇ ସର୍ବାଧିକ ପ୍ରେସକ୍ରିସନ ତାଲିକାର ୨୭୮ତମ ସ୍ଥାନରେ ଥଲା ।^[୭]

ଏହା ମଧ୍ୟ ଦେକନ୍ତୁ

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ "Vilazodone Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "VIIBRYD (vilazodone hydrochloride) tablet VIIBRYD (vilazodone hydrochloride) kit [Forest Laboratories, Inc.]". DailyMed. Forest Laboratories, Inc. December 2012. Archived from the original on 29 October 2013. Retrieved 28 October 2013.
↑ "New Medicines Newsletter" (PDF). NHS. Archived from the original (PDF) on 21 March 2019. Retrieved 21 March 2019.
↑ "Vilazodone (Viibryd) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 21 March 2019.
↑ Song, Lin; Liu, Yao; Liu, Fang; Zhang, Ruoqi; Ji, Huanhuan; Jia, Yuntao (8 September 2016). "Vilazodone for major depressive disorder in adults". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD012350.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

[AHFS2019-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ "Vilazodone Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[DM-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "VIIBRYD (vilazodone hydrochloride) tablet VIIBRYD (vilazodone hydrochloride) kit [Forest Laboratories, Inc.]". DailyMed. Forest Laboratories, Inc. December 2012. Archived from the original on 29 October 2013. Retrieved 28 October 2013.

[UK2017-3] "New Medicines Newsletter" (PDF). NHS. Archived from the original (PDF) on 21 March 2019. Retrieved 21 March 2019.

[4] "Vilazodone (Viibryd) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 21 March 2019.

[5] Song, Lin; Liu, Yao; Liu, Fang; Zhang, Ruoqi; Ji, Huanhuan; Jia, Yuntao (8 September 2016). "Vilazodone for major depressive disorder in adults". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD012350.

[NADAC2019-6] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[7] "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

[୧]

[୩]

[୨]

[୪]

[୫]

[୬]

[୭]

Clinical data

Pronunciation	/ˈvaɪbrɪd/ VY-brid
Trade names	Viibryd
Synonyms	EMD-68843; SB-659746A
AHFS/Drugs.com	monograph
MedlinePlus	a611020
data	US DailyMed: 4c55ccfb-c4cf-11df-851a-0800200c9a66
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	By mouth
Drug class	Serotonin modulator^[୧]
ATC code	N06AX24 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	72% (oral, with food)^[୨]
Metabolism	Hepatic via CYP3A4^[୨]
Elimination half-life	25 hours^[୨]
Excretion	Faecal and renal^[୨]
Identifiers
IUPAC name 5-(4-[4-(5-Cyano-1H-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide
CAS Number	163521-12-8^N
PubChem CID	6918313
IUPHAR/BPS	7427
ChemSpider	5293518^Y
UNII	S239O2OOV3
KEGG	D09698^Y
ChEBI	CHEBI:70707^N
ChEMBL	CHEMBL439849^Y
Chemical and physical data
Formula	C₂₆H₂₇N₅O₂
Molar mass	441.524 g/mol
3D model (JSmol)	Interactive image
SMILES N#Cc5ccc4[nH]cc(CCCCN3CCN(c2ccc1oc(C(N)=O)cc1c2)CC3)c4c5
InChI InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)^Y Key:SGEGOXDYSFKCPT-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)